NASDAQ: ANIKAnika Therapeutics Inc Stock
$25.79-0.16 (-0.62%)
Updated Apr 23, 2024
ANIK Price
$25.79
Fair Value Price
$21.30
Market Cap
$382.98M
52 Week Low
$16.54
52 Week High
$28.13
P/E
-4.57x
P/B
1.8x
P/S
1.99x
PEG
N/A
Dividend Yield
N/A
Revenue
$166.66M
Earnings
-$82.67M
Gross Margin
61.9%
Operating Margin
-52.58%
Profit Margin
-49.6%
Debt to Equity
0.28
Operating Cash Flow
-$2M
Beta
0.87
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
ANIK Overview
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ANIK scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANIK ($25.79) is overvalued by 21.11% relative to our estimate of its Fair Value price of $21.30 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANIK ($25.79) is not significantly undervalued (21.11%) relative to our estimate of its Fair Value price of $21.30 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANIK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANIK due diligence checks available for Premium users.
Be the first to know about important ANIK news, forecast changes, insider trades & much more!
ANIK News
Valuation
ANIK fair value
Fair Value of ANIK stock based on Discounted Cash Flow (DCF)
Price
$25.79
Fair Value
$21.30
Overvalued by
21.11%
ANIK ($25.79) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANIK ($25.79) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANIK is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANIK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.57x
Industry
29.66x
Market
41.92x
ANIK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.8x
Industry
3.71x
ANIK is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANIK's financial health
Profit margin
Revenue
$43.0M
Net Income
-$63.0M
Profit Margin
-146.6%
ANIK's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ANIK's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$270.6M
Liabilities
$58.4M
Debt to equity
0.28
ANIK's short-term assets ($163.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANIK's short-term assets ($163.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANIK's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ANIK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$3.6M
Investing
-$1.8M
Financing
$342.0k
ANIK's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANIK vs Medical Device Stocks
Anika Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.